摘要
目的探讨恩替卡韦分散片治疗慢性乙型肝炎的短期预后。方法将2016年4月～2017年10月我院接诊的60例患者纳入本研究。按照随机数字表法均分为观察组和对照组各30例。对照组采用复方甘草酸苷注射液治疗。观察组在对照组的基础上,采用恩替卡韦分散片治疗。观察两组HBV-DNA转阴情况、肝功能指标、肝纤维化指标。结果观察组治疗8周后、治疗12周后HBV-DNA转阴率高于对照组(P<0.05),观察组治疗12周后AST、TBIL、ALT水平低于治疗前和对照组(P<0.05)。观察组治疗期间不良反应发生率和对照组比较,差异无统计学意义(P>0.05)。结论恩替卡韦分散片治疗慢性乙型肝炎能够有效提高HBV-DNA转阴率,改善肝功能指标,安全性好,应用价值较高。
Objective To investigate the short-term prognosis of entecavir dispersible tablets in the treatment of chronic hepatitis B. Methods A total of 60 patients admitted in our hospital from April 2016 to October 2017 were included in the study. According to the random number table method, the patients were divided into observation group and control group, with 30 cases in each group. The control group was treated with compound glycyrrhizin injection. The observation group was given entecavir dispersible tablets on the basis of the treatment of the control group. The HBV-DNA negative condition, liver function index and liver fibrosis index were observed between two groups. Results The HBV-DNA negative rates were higher in the observation group than those in the control group after 8 weeks and 12 weeks of treatment(P<0.05). The AST, TBIL and ALT levels in the observation group after 12 weeks of treatment were lower than those before treatment and the control group(P<0.05). There was no difference in the incidence of adverse reactions during the treatment between observation group and control group(P>0.05). Conclusion The treatment of chronic hepatitis B with entecavir dispersible tablet can effectively improve the HBV-DNA negative rate, improve liver function index, and has good safety and high application value.
作者
刘希东
LIU Xidong(Department of Hepatology, Jiangxi Provincial Ping Mine General Hospital, Pingxiang 337000, China)
出处
《中国现代医生》
2019年第3期89-91,共3页
China Modern Doctor
关键词
恩替卡韦分散片
慢性乙型肝炎
短期预后
肝功能
Entecavir dispersible tablets
Chronic hepatitis B
Short-term prognosis
Liver function
